REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours
- 1 December 2014
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 25 (12), 2351-2356
- https://doi.org/10.1093/annonc/mdu465
Abstract
Brain metastases (BMs) are associated with a poor prognosis. Standard treatment comprises whole-brain radiation therapy (WBRT). As neo-angiogenesis is crucial in BM growth, combining angiogenesis inhibitors such as bevacizumab with radiotherapy is of interest. We aimed to identify the optimal regimen of bevacizumab combined with WBRT for BM for phase II evaluation and provide preliminary efficacy data. In this multicentre single-arm phase I study with a 3 + 3 dose-escalation design, patients with unresectable BM from solid tumours received three cycles of bevacizumab at escalating doses [5, 10 and 15 mg/kg every 2 weeks at dose levels (DL) 0, 1 and 2, respectively] and WBRT (30 Gy/15 fractions/3 weeks) administered from day 15. DL3 consisted of bevacizumab 15 mg/kg with WBRT from day 15 in 30 Gy/10 fractions/2 weeks. Safety was evaluated using NCI-CTCAE version 3. BM response (RECIST 1.1) was assessed by magnetic resonance imaging at 6 weeks and 3 months after WBRT. Nineteen patients were treated, of whom 13 had breast cancer. There were no DLTs. Grade 1-2 in-field and out-field toxicities occurred for five and nine patients across all DLs, respectively, including three and six patients (including one patient with both, so eight patients overall) of nine patients in DL3. One patient experienced BM progression during treatment (DL0). At the 3-month post-treatment assessment, 10 patients showed a BM response: one of three treated at DL0, one of three at DL1, two of three at DL2 and six of seven at DL3, including one complete response. BM progression occurred in five patients, resulting in two deaths. The remaining patient died from extracranial disease progression. Bevacizumab combined with WBRT appears to be a tolerable treatment of BM. DL3 warrants further efficacy evaluation based on the favourable safety/efficacy balance. ClinicalTrials.gov Identifier: NCT01332929.Funding Information
- French Health Ministry
- Comprehensive Cancer Centre François Baclesse
This publication has 21 references indexed in Scilit:
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Enhancement of radiation response with bevacizumabJournal of Experimental & Clinical Cancer Research, 2012
- Low Doses of Ionizing Radiation Promote Tumor Growth and Metastasis by Enhancing AngiogenesisPLOS ONE, 2010
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyJournal of Clinical Oncology, 2009
- Whole brain radiotherapy with radiosensitizer for brain metastasesJournal of Experimental & Clinical Cancer Research, 2009
- Angiogenesis in brain tumoursNature Reviews Neuroscience, 2007
- Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Brain metastases: epidemiology and pathophysiologyJournal of Neuro-Oncology, 2005
- Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude miceClinical & Experimental Metastasis, 2004
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and TherapyJournal of Clinical Oncology, 2002